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CHAPTER 1 - INTRODUCTION 
 
ADULT STEM CELLS 
Stem cells are undifferentiated cells with the ability to self-renew and 
differentiate into cells of different organs and tissues.1 Besides embryonic stem 
cells (ES), pluripotent cells derived from the inner cell mass of the embryo at E 
3,5 and E 4,5 in mouse and man respectively, different stem cells populations 
can be extracted from many adult and neonatal tissues.2 (fig. 1) 
These adult stem cells were originally known to be multipotent as they could 
differentiate into the cell types of the tissue of origin.3 (fig. 2) However, it is now 
accepted that they possess a certain “plasticity”, that is that they demonstrate 
the ability to differentiate also into cells of tissues and organs different from 
that of origin. 4,5  
Among various adult stem cells populations, hematopoietic stem cells (HSCs) 
were the first isolated and characterized. HSCs reside principally in bone 
marrow but they can be found also in peripheral blood and umbilical cord 
blood (UCB) and they are known to be the precursors of all blood cells.6 
In addition to HSCs, bone marrow is home to mesenchymal stromal cells, 
(MSCs) multipotent cells responsible to regenerate cells of mesenchymal origin 
in bone marrow.7 MSCs can be found also in many other adult and neonatal 
tissues, including adipose tissue, skeletal muscle, umbilical cord and placenta 
and they show the ability to differentiate into cells of mesodermal and non 
mesodermal tissues.5,8  
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Unexpectedly, adult stem cells populations were found also in tissues known 
for their low capacity to regenerate. For example, neural stem cells (NSCs), 
multipotent cells with the ability to generate neurons and glial cells were found 
in the subventricular zone of the lateral ventricles and in the hippocampus of 
postnatal and adult mammalians brain.9  
Many other stem cells types were then identified in other tissues, including 
intestinal stem cells10 and mammary stem cells11 Recently, very small 
embryonic-like stem cells (VSELs), pluripotent cells expressing ES markers, 
such as Oct3 and Nanog, were found in mouse bone marrow, brain, kidney, 
skeletal muscle and in human UCB. 12,13  
Adult stem cells reside in particular niches of the tissue of origin and they 
differentiate to replace senescent or damaged cells in response to specific 
stimuli. Moreover, they proliferate to self-renew so that the pool of tissue 
undifferentiated cells is maintained.14 On this purpose, a dividing stem cell can 
give rise to 1) two daughters identical stem cells (symmetric division), 2) two 
committed progenitor cells or 3) one stem cell and one committed progenitor 
cell (asymmetric division).15,16 
A complex loop of genetic determinants and signaling factors are known to be 
involved in maintaining the delicate balance between stem cells self-renewal 
and differentiation. In this direction, it was demonstrated that wnt proteins, a 
family of secreted molecules involved in many developmental processes, in 
both vertebrates and invertebrates, contribute to the regulation of stem cells 
self-renewal in the hematopoietic system.17 Their mechanism of action 
provides binding to specific membrane receptors that leads to the stabilization 
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and accumulation of β-Catenin in the cytosol. Consequently, β-Catenin can 
migrate to the nucleus and bind specific transcription factors to regulate target 
genes expression.18 Recently, the involvement of various microRNAs in stem 
cells gene expression regulation was studied in different pathways. For 
example, it was shown that miR-489 is able to maintain skeletal muscle 
satellite cells in a quiescence state and that, accordingly, its  down-regulation 
results in satellite cells activation.  
Moreover, miR-1 and miR-206 were up-regulated during satellite cells 
differentiation.19 Again, overexpression of miR-125b in skin stem cells 
promoted cell proliferation with a consequent increase of stem cells pool.20 
In addition, it was demonstrated that BMPs, a class of proteins belonging to 
the transforming growth factor β (TGF-β) superfamily, play important roles in 
regulation of stem cells properties.21 Their function resulted to be different 
according to the stem cells compartment, as BMPs signal induced 
osteoblastic differentiation in MSCs22 while it inhibited cells activation and 
proliferation in intestinal stem cells.23 Another class of signaling molecules 
playing key roles in stem cells fate decision is constituted by tyrosine kinase 
receptors. Indeed, fibroblast growth factor (FGF), epidermal growth factor 
(EGF) and platelet-derived growth factor (PDGF) receptors are able to regulate 
proliferation and differentiation in both ES and adult stem cells.24  
For example, in vitro studies demonstrated that FGF and EGF increase MSCs 
proliferation potential25 and EGF promotes also MSCs motility.26 
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Furthermore, it was observed that Hedgehog proteins that are involved in 
various aspects of embryonic development, can promote the proliferation of 
adult stem cells from various tissues, including HSCs27 and NSCs.28  
 
Understanding the mechanisms regulating stem cells behavior is one of the 
main goal of researchers who are studying possible applications of these cells 
in regenerative medicine and cellular therapy. To this purpose, three principal 
obstacles have to be overcome: first, the directed differentiation of stem cells 
to the desired cell type. Second, acheving high survival and functionality of 
cells after transplantation/infusion and third, avoiding undesired and 
uncontrolled proliferation of transplanted/infused cells.29 
In this regard, together with the studies above mentioned, many other 
experiments were made using natural and synthetic molecules to control stem 
cells proliferation and differentiation. Accordingly, it was observed that 
calmodulin binding motif (IQ-1), a newly discovered molecule, acts on wnt 
signaling pathway to prevent stem cells differentiation and maintain cells in a 
quiescent state till required.30 Conversely, the activation of core binding factor 
subunit alpha-1/runt related transcription factor 2 (CBFA/RUNX2) and osterix 
were seen to promote osteogenic differentiation of stem cells.31 
Various known and new chemical compounds were identified as modulators of 
stem cells fate. For example, Young and colleagues demonstrated that murine 
and human HSCs, cultured with histone deacetylase (HDAC) inhibitors, 
maintain a more primitive phenotype then control cultures.32 Interestingly, in an 
non-obese diabetic-severe combined immunodeficient (NOD-SCID) 
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repopulation assay, cells exposed to the HDAC inhibitor chlamydocin for 24 
hours displayed an average of four-fold higher engrafting ability over untreated 
cells.33 Moreover, from a screen of a heterocycle library, it was found a purine 
derivative named SR1 that increases the total number of cord blood-derived 
HSCs more than fifty-fold compared to controls.34 
In MSCs, it was observed that a trisubstituited purine, named purmorphamine, 
exerts a potent pro-differentiating activity toward osteoblasts by upregulating 
CBFA/RUNX2 expression.35 
In addition, a variety of other small molecules and chemicals with MSCs 
differentiation inducing activity were identified. For instance, 5-Aza-
2’deoxycytidine (decitabine, trade name Dacogen) promoted the multi-lineages 
differentiation of mesenchymal precursor cell line C3H10T1/2 into osteoblasts, 
adipocytes and chondrocytes, by converting the cells into a competent 
spontaneous differentiation state accounting for its pleiotropic effect.36 
Furthermore, it was shown that reversine, a synthetic purine known for its 
potential of reversing adult cells into a multipotent state37,38,39 is able to increase 
differentiation potential of bone marrow (B) and adipose-derived (AD) MSCs.40 
To discover novel mechanisms involved in NSCs self-renewal, Diamandis and 
colleagues conducted a cell-based screen with a library of active compounds 
for those that inhibited neurospheres proliferation of mouse NCSs. Various 
compounds were found, including dihydrocapsaicin and apomorphine, 
agonists of the vanilloid receptor and of the dopamine receptor, respectively.41 
Other molecules were then investigated for their role in NSCs differentiation. 
On this line, the natural product forskolin (FSK) demonstrated the ability to 
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promote neurogenesis in NSCs by blocking hedgehog signaling.42 Moreover, a 
2-substituted aminothiazol named neuropathiazol induced the differentiation 
into βIII-tubulin positive neurons of up to 80% of cells.33 
Recently, apart from proteins and chemicals, mechanical means were 
observed to be involved in stem cells differentiation. Indeed, physical 
properties of extracellular matrix were modulated to control osteogenic and 
chondrogenic differentiation of stem cells.43 Furthermore, it was reported that 
manipulation of the membrane potential of cultured MSCs can influence their 
fate and differentiation.44 
Although, to the present, researchers are not completely able to control and 
drive stem cells fate, the use of these cells to treat different pathologies in 
animal models or in humans showed encouraging results. In this regard, fetal 
and adult NSCs were used to repair damaged nervous tissue in mice 
presenting different brain affecting diseases.7 In an animal model of Parkinson, 
NSCs transplantation led to significant cellular and functional improvement.45 
Moreover, in an animal model of Alzheimer, injection of NSCs into the basal 
part of forebrain led to an increase of cholinergic neurons and to an improve of 
cognitive ability respect to untreated controls.46 Other studies were conducted 
on using NSCs in spinal cord injury. In this direction, Yan and colleagues 
injected NSCs into the spinal cord of rats with spinal cord injury and observed 
that these cells differentiated into neurons and created axons and synapses 
with host neurons.47 
HSCs were mostly utilized to treat various blood and bone marrow related 
cancers, such as leukemia and multiple myeloma. An analysis of 586 adult T-
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cell leukemia-lymphoma patients who received allogeneic HSCs 
transplantation revealed that HSCs therapy was effective for improving long-
term survival in these patients.48 Furthermore, HSCs transplantation was tested 
also in other experimental therapies, including lysosomal storage diseases 
(LSDs), Hurler syndrome and X-linked adrenoleukodistrophy, leading to 
improved patients survival rates.7 However, these promising results were offset 
by several negative side effects, including graft versus host disease (GVHD) 
which may lead to lethal complications in patients.49 Hence, further studies will 
be essential for enhancing the safety and effectiveness of HSCs 
transplantation. 
MSCs were largely studied and analyzed for their potential in many cell therapy 
and medicine regenerative approaches. Their features, potentiality and use are 
discussed in detail in the next session.  
 
 
. 
 
 
	   14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Examples of human adult stem cells sources 
 
Figure 1 Embryonic stem cells isolation  
               and differentiation 	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MESENCHYMAL STROMAL CELLS 
  
MSCs were first described about forty years ago by Friedenstein and 
colleagues, and they were defined as adherent cells with a fibroblast-like 
appearance capable of differentiating into osteocytes, chondrocytes, 
adipocytes, tenocytes and myocytes.8,50  
Today, MSCs can be isolated from almost any adult tissues, including bone 
marrow, adipose tissue, tendon, skeletal muscle, skin and liver.51,52 At the same 
time, they can be obtained from some neonatal tissues, including: umbilical 
cord (UC), umbilical cord blood (UCB) and particular parts of the placenta.53,54 
MSCs derived from different sources show similar cellular and molecular 
features. However, many publications reported that they have some 
differences in their proliferation rates, surface markers expression and, most 
importantly, multipotency. Normally, as possibly expected, MSCs obtained 
from neonatal tissues show higher expansion and engraftment capacities 
compared to MSCs derived from adult tissues.52 On the other hand, the 
success rate of cell isolation from UCB is normally lower when compared to 
those from adult bone marrow and adipose tissue.55 In addition, Al-Nbaheen 
and colleagues reported that MSCs derived form different adult tissues 
showed heterogeneity in surface marker expression. For example, ADMSCs 
expressed notably lower levels of CD146 marker in respect to BMSCs and skin 
MSCs. Moreover, it was observed that BMSCs possess a higher differentiation 
potential toward osteoblasts than toward adipocytes while skin MSCs act in 
the opposite manner.52,56 
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Interestingly, it has been reported that heterogeneity in cellular morphology, 
differential markers expression and variable differentiation potential, occurs 
also within a single MSCs population as a possible reflex of the repertoire of 
distinct subpopulations existing in vivo.57 In this direction, it was demonstrated 
that MSCs of a single cell-derived colony, simultaneously express mRNAs 
characteristic of various committed mesenchymal cell lineages including 
osteoblasts, chondrocytes and myoblasts.58  
Post and colleagues provided evidence that BMSCs contain lineage-
committed populations of pre-osteoblastic and pre-adipocytic cells. The 
authors isolated two clonal cell lines called mMSCs1 and mMSCs2 from 
murine bone marrow. MMSCs1 presented a round morphology and they were 
able to differentiate toward adipocytes, but failed the differentiation toward 
osteoblasts. On the contrary, mMSCs2 had a fibroblast-like morphology and 
they were able to differentiate toward osteoblasts, but failed to differentiate 
toward adipocytes.59 This behavior suggests the presence of a lineage 
“imprinting” in different stromal cells compartments that influences the 
differentiation potential of MSCs. 
Along this line, it was demonstrated that human BMSCs possess specific 
features according to their in situ localization; for example, the expression of 
CD146 marker was found in endosteally localized CD271+ MSCs but lacks in 
perivascular CD271+ MSCs.60 
On the other hand, heterogeneity within a single MSCs population could be the 
effect of the alterations induced by extensive ex vivo culturing. 
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In this direction, it was observed that long term culture induces MSCs to 
change surface molecules expression profiles, to decrease the ability to 
differentiate toward mesodermal lineages61,62 and to increase cell size and signs 
of cell aging.63 Long term culture was further associated with continuous 
changes in the global gene expression profile64 and DNA methylation,65 
accounting for the phenotypic variations occurring in these cells. Moreover, 
during cell isolation process, the detachment of MSCs from their original niche 
could induce partial cell differentiation, yielding a mixture of cells at various 
degree of maturation and consequently variable in morphology and 
phenotype.64 
In addition to their heterogeneity, the lack of universally accepted criteria to 
define and characterize MSCs, had fatherly complicated the study of these 
cells, leading to incongruences among investigators. To address this problem, 
the Mesenchymal and Tissue Stem Cell Committee of the ISCT recently 
proposed a set of standards to define human MSCs. 
First, MSCs must be plastic-adherent when maintained in standard in vitro 
culture conditions. Second, ≥95% of the MSCs population must express 
CD105, CD73, CD90 and must lack the expression (≤ 2% positive) of CD45, 
CD34, CD14 or CD11b, CD79a or CD19 and HLA class II, as measured by 
flowcytometry. Third, the cells must be able to differentiate into osteoblasts, 
adipocytes and chondroblasts under in vitro standard differentiating 
conditions.66 
Methodology employed in the isolation and enrichment of MSCs is reliant to 
the ability of these cells to adhere to and subsequently proliferate on tissue 
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culture plastic. Pre-enrichment using cocktails of antibodies or Ficoll gradient 
separation, that deplete contaminating cell populations, are the most widely 
used means for MSCs isolation.67 In recent years, there was great interest in 
founding cellular markers that can strictly characterize MSCs for their direct 
isolation from tissues. To this purpose, some cellular surface markers were 
proposed, including stage-specific embryonic antigen- (SSEA-) 1 in mice and 
SSEA-4 or STRO-1 in humans.68,69,70 
Quirici and colleagues used CD271 as a marker for direct isolation of human 
BMSCs and ADMSCs. The authors showed that the immunomagnetic sorting 
of MSCs labeled with antibodies against CD271 allows the selection of 
phenotypically and functionally homogeneous cells that are capable of 
expansion, self-renewal, and differentiation into multiple mesenchymal 
lineages.71,72 
However, to date, there are not any available effective and reproducible 
methods for purification of MSCs, as no specific surface markers were found. 
Indeed, currently used markers are also expressed by other cells, including 
stromal and dermal fibroblasts.73 
The multipotent differentiation ability of MSCs is a very important feature of 
these cells. Due to their mesodermal origin, MSCs were regarded as an 
attractive source for the generation of cells of mesodermal origin such as 
osteoblasts, adipocytes and chondroblasts.74 However, recent publications 
reported that different MSCs population have also the potential to differentiate 
into several additional cell types, including skeleton75, smooth76 and cardiac 
muscle cells.77  
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Interestingly, MSCs could generate neuron-like cells in vitro78 and astrocytes 
and neurons after implanting into the mouse brain in vivo.79 Moreover, Jiang 
and colleagues demonstrated that BMSCs, transplanted in a non-damaged 
recipient, engraft and differentiate to the hematopoietic lineage, in addition to 
the ephitelium of liver, lung and gut. Accordingly, it was observed that BMSCs, 
injected in a murine blastocyst, contribute to most somatic cell types.5 
Despite the above discussed difficulties in MSCs isolation, characterization 
and manipulation, their multi-lineages differentiation ability gives to these cells 
a great potential for clinical application in regenerative medicine and cell 
therapy. On this line, it was recently shown that MSCs can also secrete a 
variety of pro-regenerative molecules that stimulate survival and proliferation of 
cells and increase angiogenesis in the injured tissue.80    
Animal models provided a useful tool for defining a number of diverse 
prospective applications for MSCs in tissues repair.  
For example, MSCs loaded onto a porous ceramic cylinder provided significant 
healing potential in critical size bone defects in the canine model.81 
Furthermore, MSCs loaded onto macroporous hydroxyapatite scaffods 
promoted full limb functional recovery in a significantly shorter period than for 
traditional bone grafting.82 Wakitani ad colleagues utilized MSCs to treat full 
thickness cartilage defects in a rabbit model obtaining the total repair of 
subchondral bone two weeks after implantation.83 
In comparison to animal studies, there are less reports outlining the role of 
MSCs in promoting bone and cartilage repair in the human clinical setting. 
However, some positive results were obtained including two patients with full 
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thickness articular patellar defects and an athlete with a full thickness articular 
cartilage defect of the femoral condyle.84,85 
In late years, researchers studied the role of MCSs in repairing many other 
different tissues, such as cerebral and cardiac tissue. In a rat model of middle 
cerebral occlusion, MSCs administration led to significant reduction in gross 
lesion volume and improved functional recovery.86 Furthermore, in a clinical 
trial, autologous transplantation of MSCs in 30 patients with middle cerebral 
artery infarcts and neurological deficits resulted in evident improvement, 
without any adverse reactions after serial follow-up evaluations.87 Other clinical 
and experimental evidences indicated that MSCs are a promising cell type for 
the treatment of cardiac dysfunction, independently from their myogenic 
differentiation capacity. Indeed, their beneficial effect was attributed in part to 
their propensity to secrete pro-survival and pro-angiogenetic factors.88,89  
In this direction, in a randomized double-blinded study, patients receiving 
infusions of MSCs post myocardial infarction demonstrated significant 
enhancement in cardiovascular function.90 Moreover, similar therapeutic 
benefits were reported in patients receiving intracorony MSCs administration 
compared to placebo.91 
 Allogenic transplantation of MSCs was useful also in treating genetic bone 
disorders, such as osteogenesis imperfecta (OI) and hypophosphatasia. In vivo 
murine models of OI demonstrated selective incorporation of MSCs in bone 
tissue with subsequently reduced fracture rates and increased bone strength.92 
Successful in utero-transplantation of MSCs was reported in a human fetus 
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with severe OI who after birth demonstrated regular growth and psycomotor 
development.93 
In addition, thanks to their remarkable immunosuppressive properties, MSCs 
were used to treat immune-associated conditions such as GVHD Indeed, 
MSCs were known to suppress T-lymphocytes and NKCs functions and to 
induce regulatory T lymphocytes activation.94 Furthermore, these cells could 
secrete soluble factors that inhibit B lymphocytes differentiation and impair 
their chemotaxis.95 
 Animal models of GVHD suggested that BMSCs and ADMSCs have the same 
immunosuppressive effect and lead to significant symptomatic 
improvement.96,97 Moreover, encouraging results were obtained also in human; 
in a phase II clinical trial on patients with steroid-resistant, acute GVHD, MSCs 
treatment led to lower transplantation related mortality and higher two-year 
survival post MSCs transplantation.98 
 
The promising results obtained with clinical applications of MSCs induced 
many researchers to focus their attention on the study of these cells and their 
possible application. In this context, this Ph.D. project was dedicated to the 
research of new possible surface markers for the identification, 
characterization and possibly isolation of human BMSCs. Moreover, new 
candidate molecules involved in the differentiation of MSCs were investigated.  
In this direction, we focused our attention on sphingolipids, a family of lipids 
found in the outer leaflet of cell plasma membranes and involved in many cell 
signaling pathways. The physiological and pathological role of sphingolipids in 
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the cell, which is the basis of the hypothesis of their involvement in stem cell 
differentiation, are discussed in the next section of this thesis. 
 
 
SPHINGOLIPIDS 
 
Sphingolipids (SLs) are a class of lipids composed by a long-chain sphingoid 
base as backbone. Sphinganine and sphingosine are the most common 
sphingoid bases found in SLs even if others were described, including 
phytosphingosine and methylsphingosine.99 
Ceramide, the simplest SL, consists of a sphingoid base to which a fatty acid 
is attached at C-2 via N-acylation. In nature, different ceramides exist 
depending on the N-fatty acyl chain that can contain from two to twenty-eight 
carbon atoms.100 In the cell, ceramide synthesis occurs in the cytosolic leaflet 
of the endoplamic reticulum (ER) and begins with the condensation of serine 
and palmitoyl CoA to form 3-ketosphinganine, which is subsequently reduced 
to produce sphinganine. Dihydroceramide, formed by sphinganine acylation is 
then converted into ceramide by the insert of a trans 4-5 double bond.101  
In addition to de novo synthesis above mentioned, ceramide can be also 
generated from rapid hydrolysis of sphingomyelin (SM) by acid 
sphyngomyelinases (aSMases) in the lysosome or neutral sphyngomyelinases 
(nSMases) at the plasma membrane.102 Moreover, besides these pathways, 
other observations provided evidence for ceramide generation from the 
processing glycophigolipids (GSLs) at the plasma membrane.103 
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Ceramide is the key hub in the SL biosynthetic pathway and it may be 
converted into a variety of metabolites. Deacylation by ceramidases enzymes 
acting in different cell compartments, including lysosomes,104 plasma 
membrane105 and endoplasmic reticulum (ER)/Golgi complex,106 yields 
sphingosine, which may be phosphorylated by sphingosine kinase to 
sphingosine-1-phosphate (S1P).  
In addition, ceramide may be converted to ceramide-1-phosphate by ceramide 
kinase (C1P) or transported to the Golgi complex to be coverted to SM by the 
tranfer of phosphorylcoline via SM synthase.102 The importance of the 
equilibrium between SLs biosynthesis and degradation is underlined by 
different diseases associated with defects of the enzymes involved in these 
pathways. 
In this regard, mutations in SMPD1 gene encoding aSMase cause different 
forms of Niemann-Pick disease, including type A characterized by severe 
neurovisceral phenotype and type B exhibiting little neural degeneration with 
frequent liver and spleen pathologies.107 Moreover, deficiencies in acid 
ceramidases lead to Farber disease, a disorder characterized by the 
accumulation of ceramide in cells with consequent impairment of tissues 
functionality.108  
SLs are fundamental structural components of cell membranes as well as 
mediators of cell signaling of different physiological and stress stimuli.102  
The main pathways in which SLs are involved are: 
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CELL DEATH PATHWAY. Ceramide is involved in cell growth arrest and 
apoptosis, through different mechanisms of action: first, it acts as a second 
messenger binding several intracellular targets, including the protein kinase C 
(PKC),109 kinase suppressor of Ras (KSR)110 and Raf-1.111 In this direction, it 
was demonstrated that ceramide mediates tumor necrosis factor- (TNF-) 
induced cell death by activating directly endosomal protease cathepsin D. 
Direct binding of ceramide to cathepsin D resulted in autocatalytic proteolysis 
of the 52 kDa pre-pro cathepsin D to form the enzymatically active 48/32 kDa 
isoforms.112 
Second, ceramide could act directly on mitochondria interacting with 
components of the mitochondrial electron transport chain, accounting for the 
stimulation of ROS production and mitochondrial depolarization observed 
during apoptosis.100 Indeed, in cell-free assays using purified rat liver 
mitochondria, it was shown that the addition of ceramide directly induces a 
burst of ROS generation and blockade of the mitochondrial electron 
transfer.113,114 
Third, ceramide, generated within membrane lipid rafts through SMases action, 
could self-associate and induce raft coalescence into large transmembrane 
signaling platforms that are involved in death signaling for diverse cellular 
stresses, such as physical stresses, bacterial and viral infections, 
chemotherapy and inflammatory mediators.115,116 
 
PRO-SURVIVAL PATHWAY. In contrast to ceramide, S1P and C1P function as 
pro-survival molecules. It was shown that S1P act as second messenger to 
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mediate calcium homeostasis, cell growth and suppression of apoptosis.117 
Interestingly, it was postulated that S1P could also have trophic effects on 
skeletal muscle. In this regard, it was demonstrated that exogenous application 
of S1P counteracts the reduction of rat soleus muscle mass caused by 
denervation, whereas neutralization of the extracellular lipid with a specific 
anti-S1P antibody accelerates the denervation-induced atrophy.118 C1P was 
observed to share similar functions of S1P, exerting its anti-apoptotic function 
through the inhibition of protein phosphatase 1 (PP1).119 
 
PRO-ANGIOGENETIC PATHWAY. It was observed that S1P stimulates 
angiogenesis in vivo via S1P1 and S1P2 receptors in the Matrigel implant 
assay.120 Moreover, it was demonstrated that, in vascular endothelial cells, S1P 
and its receptor S1P1 are essentially required for the recruitment process of 
pericytes and smooth muscle cells to the nascent capillaries and thus vascular 
maturation.121,122 Accordingly, it was recently shown that intramuscular 
administration of S1P, in mouse hindlimb after ischemia, is useful to neo-
vessels formation and consequent acceleration of blood flow recovery.123 
 
The studies of physiological role of SLs were crucial to understand the 
contribute of SLs in various disease processes. In this regard, it was 
demonstrated that ceramide can inhibit insulin-stimulated glucose uptake, 
glucose transporter type 4 (GLUT4) translocation and glycogen synthesis, 
contributing to the development of insulin resistance resulting from lipid over-
supply.124 The inhibitory effect of ceramide on insulin signaling mainly resulted 
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from its ability to block the activation of akt/protein kinase B, a central 
mediator of insulin action.125 Confirming this thesis, it was observed that in 
myotubes derived from C2C12 cell line, palmitate increases ceramide content 
with subsequent inhibition of downstream insulin-stimulated Akt 
phosphorylation.126 Recently, it was shown that SK1/S1P axis is also crucially 
implicated in the regulation of glucose metabolism in skeletal muscle. Indeed, 
pharmacological or siRNA-mediated inhibition of SK1 resulted in an 
appreciable decrease in basal and insulin-stimulated glucose uptake in C2C12 
myoblasts. Moreover, overexpression of SK1, which caused an increase of 
intracellular S1P levels, enhanced basal and insulin-stimulated glucose 
uptake.127 
In addition, SLs were investigated for their involvement in in the pathogenesis 
of cystic fibrosis, an autosomal recessive disorder caused by mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR).128 Indeed, 
ceramide produced from SM at the plasma membrane was able to inhibit 
cyclic adenosine monophosphate (cAMP)-mediated anion transport by 
CFTR.129 Another study demonstrated that fenretinide, which upregulates de 
novo ceramide synthesis, reduces interleukin-8 (IL-8)-mediated inflammation in 
CFTR-deficient lung epithelial cells.130 
As ceramide is known to be involved in cell death signaling, it was postulated 
that it could have anti-carcinogenic activity. In this direction, it was shown that 
direct administration of ceramide induces apoptosis in cancer cells and cancer 
cell lines.131,132 De novo ceramide synthesis was altered in human head and 
neck carcinomas and was implicated in caspase-dependent cancer cell death 
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pathway.133 Furthermore, the effectiveness of some chemotherapeutic agents 
appeared to be related to their ability to activate ceramide-mediated 
apoptosis.134  
 
 
GLICOSPHINGOLIPIDS 
 
The attachment of a sugar head group to ceramide gives origin to the most 
structurally complex class of SLs: GSLs. After being synthetized in the ER, 
ceramide can be delivered by vesicular transport to the Golgi apparatus where 
GSLs synthesis occurs. Here, the transfer of a glucose or a galactose residue 
by specialized glycosyltransferases to ceramide lead to the formation of 
glucosylceramide (GlcCer) or galactosylceramide (GalCer) respectively, the 
precursors of all known GSLs. GalCer can be subsequently modified into 
sulfatides while GlcCer can be converted into more complex GSLs through 
sequential transfer of sugars by different glycosyltransferases.135 Many different 
carbohydrates structures were described in GSLs with the main sugars being 
glucose, galactose, fucose, N-acetylglucosamine, N-acetylgalactosamine and 
sialic acid. Based on their core carbohydrate structures, GlcCer-derived GSLs 
are classified in different series, the main common being ganglio- (Galß1-
3GalNAcß1-4Galß1-4Glcß1-1’Cer), lacto- (Galß1-3GlcNAcß1-3Galß1-4Glcß1-
1’Cer) and globo-(GalNAcß1-3Gala1-4Galß1-4Glcß1-1’Cer) series. Moreover, 
they can be subdivided into neutral and acidic GSLs. Acidic GSls containing 
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one or more sialic acid residues are referred to as gangliosides as they are 
particularly abundant in nervous tissue.136 
The catabolism of GSLs proceeds by stepwise, sequential removal of sugars 
by lysosomal exohydrolases to the final common products, sphingosine and 
fatty acids. In this process, non-enzymatic proteins such as saponins are 
essential either by presenting lipid substrates to their cognate enzymes, or by 
interacting with specific enzymes.137  
Various severe diseases caused by deficit in GSLs metabolism were described. 
On this line, disrupted gangliosides synthesis in mice with either GM3 
synthase,138 GM2/GD2 synthase139 or GD3 synthase140 knocked out, caused 
differential neurological impairments. Again, in mice with GlcCer synthase 
knocked out, it was shown early embryonic lethality.141 In humans, a loss-of-
function mutation in GM3 synthase gene was identified in a cohort 
characterized by autosomal recessive infantile-onset epilepsy syndrome.142 
Moreover, a patient with GM2/GD2 synthase deficiency died at three month 
after presenting abnormal motor function and seizures.143 Conversely, defects 
in GSLs hydrolases result in excessive accumulation of specific GSLs in 
lysosomes leading to various LSDs. For example, Fabry disease, due to the 
deficiency of alpha-galactosidase, the enzyme that cleaves principally 
globotriaosylceramide (Gb3), is characterized by Gb3 accumulation in many 
tissues and organs leading mainly to cardiac and cerebrovascular 
complications.144 Tay-Sach disease is another known LSD caused by defect of 
β-hexosaminidase A with consequent GM2 accumulation leading to 
neurological complications.145 
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GSls are localized in cellular membranes and principally at the plasma 
membrane.  
Here, the long hydrocarbon chains of ceramide drive them to partition laterally 
into lipid rafts, cholesterol-rich membrane microdomains146 known for their 
involvement in cell signaling transduction. GSLs bind many different interactors 
and are involved in many different physiological and pathological signaling 
pathways acting as: 
 
VIRUSES AND TOXINS RECEPTORS. It has long been known that GSls can 
act as receptors for viruses and toxins promoting their internalization into the 
cell. In this regard, it was demonstrated that acid sialic residues on 
gangliosides participate in influenza virus internalization,147 whereas some cell 
surface GSLs interact with different components of the human 
immunodeficiency virus (HIV) fusion machinery.148 Moreover, it was observed 
that ganglioside GM1 and Gb3 function as receptors for cholera toxin and 
shiga toxin respectively, promoting their internalization by the cell.149,150 
GSLs were then investigated also for their involvement in post-infectious 
disease, such as Guillain-Barrè or Miller-Fisher syndromes. Indeed, IgG 
antibodies directed against pathogen antigens such as lipopolisaccaride of C. 
jejuni cross-react with host gangliosides causing autoimmune pathologies.151 
 
CELL-CELL INTERACTION MEDIATORS. GSls are involved in glycan-driven 
cell-cell recognition systems through the interaction with other GSls or with 
lectins.  
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It is known that lectins E-selectin and P-selectin expressed on the endothelium 
bind to sialic acid- and fucose-containing glycans on neutrofils, event that 
promotes neutrofil adhesion to endothelium and squeeze into the surrounding 
tissue.152 Interestingly, it was shown that while P-selectin binds to 
glycoproteins, E-selectin receptors are fucosylated gangliosides with very long 
chain poly N-acetyl-D-lactosamine (LacNac) structures.132 Furthermore, it was 
demonstrated that natural killer cells (NKCs) express a specific lectin named 
Siglec- (sialic-acid binding immunoglobulin-like lectin-) 7, which binds 
preferentially b-series gangliosides expressed on other cells with consequent 
modulation of NKCs activity.153 Indeed, cells overexpressing the b-serie 
ganglioside GD3 suppressed NKCs-mediated cytotoxicity in a siglec-7 
dependent manner.154 Another member of siglec family, siglec 4, is known to 
be expressed in nerve tissue by cells that form myelin155 (where it binds to 
gangliosides to stabilize axon-myelin interaction and regulate axon outgrowth 
after injury. As confirmation, B4galnt1- (GM2/GD2 synthase) null mice 
displayed axon degeneration and dysmyelination similar to that found in sigle-
4-null mice.156 In addition, St3gal5/B4galnt1 (GM3 and GM2/GD2 synthases) 
double-null mice showed severe disruptions in axon-myelin interactions.157 
 
MEMBRANE RECEPTORS MODULATORS. Modulation of GSLs expression 
can have profound effects on the activity of various tyrosine kinases receptors, 
including insulin receptor (IR), epidermal growth factor receptor (EGFR) and 
vascular endothelial growth factor receptor (VEGFR). 
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IR regulation by gangliosides was demonstrated in various systems: first, 
addition of gangliosides to partially purified IRs reduced insulin-stimulated 
tyrosine phosphorylation.158 Second, in a cellular model of insuline resistance, 
the attenuation of IR signaling, induced by TNF-alpha, was accompanied by 
elevated GM3 biosynthesis. Moreover, pharmacological block of gangliosides 
biosynthesis could reverse the effect of TNF-alpha.132 Third, in an in vivo 
model, St3gal5- (GM3 synthase) null mice, which lack GM3 and downstream 
gangliosides, had enhanced insulin sensitivity with increased IR 
phosphorylation in skeletal muscle.159 GM3 action on IR inhibition, appears to 
be due to a direct binding ganglioside-receptor as a site-directed mutagenesis 
study identified a cationic residue (Lys-944) required for IR-GM3 interaction.160 
In addition to its effect on insulin signaling, ganglioside GM3 has long been 
known to inhibit EGFR tyrosine kinase without interfering with EGF binding.161  
A recent study by Coskun and colleagues demonstrated that GM3 limits 
receptor dimerization and autophosphorylation. This GM3-mediated inhibition 
can be overcome by the EGF ligand and relies on the direct interaction 
between GM3 sialic acid with an extracellular lysine localized proximally to the 
EGFR transmembrane domain162 
Gangliosides participate also in VEGFR signaling. Indeed, addition of 
ganglioside GD1a enhanced VEGF-induced VEGFR phosphorylation with 
consequent proliferation of vascular endothelial cells in vitro.163  Moreover, 
GD1a increased the expression of VEGFR and reduced the concentration of 
VEGF required to induce receptor activation. On the contrary, ganglioside GM3 
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was able to inhibit VEGFR phosphorylation and to reduce VEGF-induced 
proliferation in vitro and angiogenesis in vivo.164 
 
EXTRACELLULAR AND INTRACELLULAR CELL SIGNALING MEDIATORS. α-
GalCer, a GSL derived from marine sponge, is able to bind and activate a 
special subset of immune T cells, invariant NKCs (iNKCs). Accordingly, it was 
observed that following α-GalCer binding, iNKCs rapidly secreted IL-4 and 
interferon-γ with consequent transactivation of various cells of the innate and 
adaptive immune system.165  
Gangliosides were also proposed as intracellular mediators involved in different 
cellular pathways. Ganglioside GD3 was known to act as pro-apoptotic factor 
in different cell types. Indeed, in human hemopoietic cell lines, GD3 rapidly 
accumulated upon CD95 triggering or ceramide stimulation with consequent 
cell apoptosis. In addition, CD95- and ceramide-induced apoptosis could be 
blocked if endogenous GD3 accumulation was prevented by suppressing GD3 
synthase expression.166 It was demonstrated that the pro-apoptotic function of 
GD3 is explicated at different levels: it can directly target mitochondria 
inducing the loss of mitochondrial potential, release of ROS followed by 
cytocrome C release and caspases activation.167 Moreover, GD3 can block the 
activation of the nuclear receptor NF-kB and consequently the transcription of 
NF-kB-dependent pro-survival genes by preventing NF-kB translocation from 
the cytosol to the cell nucleus.168 
! 33 
 
Figure 3 The metabolism of SLs and GSLs in the ER and Golgi apparatus. 
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GSLs AND ADULT STEM CELLS 
 
Recently, researchers developed great interest in the study of GSLs expression 
and role in stem cells. Because of their principal localization in the outer leaflet 
of plasma membranes, GSLs were seen as possible marker molecules for 
different stem cells characterization and isolation. Moreover, it was shown that 
GSls are involved in many different stem cells signaling pathways, including 
proliferation, differentiation and apoptosis. The main studies relating GSLs in 
NSCs, HSCs and MSCs are discussed below.  
 
NEURAL STEM CELLS 
It was reported that NSCs express principally b-series gangliosides such as 
GD2, detected only by immunological techniques169 and GD3, biochemically 
detected by thin-layer chromatography. Along this line, ganglioside GD3 was 
then proposed by Nakatani and colleagues as unique and powerful cell-surface 
marker to identify and isolate NSCs from brain. In this work, they demonstrated 
that GD3 is expressed in more than 80% of NCSs prepared from postnatal and 
adult mouse brain tissues and its expression decreases drastically with cell 
differentiation. Moreover, GD3+ cells isolated from postnatal and adult mouse 
subventricular zones, efficiently generated neurospheres compared to GD3- 
cells and possessed multipotency to differentiate into neurons, astrocytes and 
oligodendrocytes.9  
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 SSEA-1 and SSEA-4 antigens were also investigated as possible NSCs 
specific surface markers. In this direction, NSCs prepared from mouse brains 
at postnatal day 1 and from human brains at gestational week 17 expressed 
SSEA-1 by flow cytometry analysis.170 Furthermore, SSEA-1+ cells isolated 
from the subventricular zone had characteristics of NSCs.171  
In human forebrains, SSEA-4 was found expressed in CD133+ NSCs and 
CD133+/SSEA-4+ cells isolated by FACS were able to form neurospheres and 
to differentiate to neurons and astrocytes.172 
GSLs resulted useful for isolating not only NSCs but also glial precursor cells, 
progenitors cells that could differentiate to type-2 astrocytes and 
oligodendrocytes. Indeed, GT3 and O-acetyl GT3 were recognized as glial 
precursor cells markers and they were used to enrich these cells from a 
heterogeneous population of rat NSCs by magnetic cell sorting.173 GSLs were 
then studied for their role in regulating NSCs behavior and differentiation. In 
this regard, gangliosides pattern of neuroepitelial cells was modulated during 
neuronal differentiation. Indeed, a-series gangliosides such as GM1 and GD1a, 
not expressed in neuroepithelial cells, became detectable after nueronal 
differentiation.174 Moreover, depletion of GSLs by a GSLs synthesis inhibitor, 
repressed the activation of Ras-mitogen-activated protein kinase (MAPK) 
pathway and retarded mouse neuroepithelial cells proliferation.175 
 
HEMATOPOIETIC STEM CELLS 
To date, few information on HSCs GSLs are available. One of the first works on 
GSLs pattern of HSCs were conducted in rat lymphocyte progenitor cells 
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prepared from bone marrow by Ficoll gradient centrifugation. Here, 
gangliosides were biochemically quantified founding tetrasialogangliosides as 
major components and disialogangliosides as minor components.176 
Furthermore, it was found that cholera toxin, a molecular probe recognizing 
GM1, is reactive to mouse HSCs suggesting the presence of GM1 in these 
cells.177 However, as it is known that cholera toxin also binds to a lesser extent 
other gangliosides such as asialo-GM1, fucosyl-GM1 and GD1a,178 the 
presence of GM1 should have been confirmed by biochemical analysis.  
 
MESENCHYMAL STROMAL CELLS 
GSLs expression and role in MSCs derived from different tissues was 
investigated by various researchers. In this regard, it was reported by Gang 
and colleagues that SSEA-4 antigen can be a good marker for mouse and 
human BMSCs. Along this line, SSEA-4+ cells isolated by FACS showed high 
proliferative ability and could differentiate into osteoblasts and adipocytes.69 
Subsequently, SSEA-4 expression was found also in human UCB-derived 
MSCs by mass spectrometry and immunological techniques. However, this 
marker can not be considered optimal for these cells as its expression resulted 
to be altered by cell culture conditions.179 
Martinez and colleagues proposed ganglioside GD2 as a novel surface marker 
for human BMSCs. Using immunological techniques, they observed that MSCs 
are the only cells within normal marrow presenting GD2 and its expression is 
stably mantained after in vitro cells expansion. Furthermore, GD2+ cells 
isolated from bone marrow by immunomagnetic selection presented 
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differentiation capacity to osteoblasts, adipocytes and chondroblasts.180 On the 
same line, it was shown that GD2 is expressed in UCB-derived MSCs and it 
identifies a subpopulation of cells with high clonogenicity and proliferation 
capacity as well as strong multi-differentiation potential. GD2+ sorted cells 
showed increased expression of typical ES markers, such as SSEA-4, Oct-4, 
Sox-2 and Nanog.181 Moreover, inhibition of GD2 synthesis in UCB-derived 
MSCs suppressed neuronal differentiation and down-regulate helix-loop-helix 
(HLH) transcription factors which are involved in early neuronal 
differentiation.182 
Besides their possible role of specific markers for MSCs isolation, GSLs were 
investigated for their possible involvement in MSCs differentiation. Different 
works demonstrated that GSLs pattern of MSCs significantly change when 
cells are induced to differentiate. In this direction, ganglioside GT1b was found 
in 9-old differentiated neuronal cells derived from periodontal MSCs but not in 
starting stem cells. In addition, it was observed that in dental pulp-derived 
MSCs, knockdown of GlcCer synthase by small hairpins RNAs, leading to the 
lack of all GSLs derived from GlcCer, causes the inhibition of neuronal 
differentiation.183  
Lee and colleagues showed that human ADMSCs express gangliosides GM3, 
GM2 and GD1a and they registered an increase of GD1a after 5 days 
differentiation toward osteoblasts.184 Moreover, in MSCs from dental pulp, it 
was observed an increase of ganglioside GD1a together with a decrease of 
ganglioside GM3 during differentiation toward osteoblasts. In addition, an 
increment in the activation of alkaline phosphatase, a well known marker of 
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osteogenic differentiation, was reported in these cells in response to treatment 
with GD1a together with EGF.185 Yang and colleagues then demonstrated that 
inhibition of GD1a synthesis, by ST3Gall II (GD1a synthase) silencing, 
suppresses differentiation of human MSCs toward osteoblasts.186 
 Recently, it was speculated that S1P participates in BMSCs differentiation 
toward hepatic myofibroblasts through tumor growth factor (TGF) β-induced 
sphingosine kinase (SK) activation and S1P receptors recruitment. In favor of 
this hypothesis, pharmacological or siRNA inhibition of SK1 abrogated the pro-
differentiating effect of TGF-β1.187 Moreover, using S1P specific antagonists, it 
was demonstrated that the pro-differentiating effect of TGF-β1 is mediated by 
S1P receptors.188 S1P and SM metabolism were also implicated in the 
activation of satellite cells, stem cells resident in skeletal muscle known to 
carry out muscle regeneration processes. Nagata and colleagues observed 
that, in quiescent satellite cells, levels of plasma membrane SM considerably 
decrease with consequent increase of intracellular S1P, which mediates the 
entry of satellite cells into the cell cycle.189,190 Moreover it was reported that, 
along with a pro-myogenic effect, S1P also exerts anti-migratory action in 
C2C12 myoblasts needed for the establishment of cell-cell contact and fusion 
to form myotubes.191 
SLs are involved also in other MSCs signaling pathway, including apoptosis. In 
this regard, it was observed that ceramide causes a loss of cell viability in a 
concentration- and time-dependent manner in ADMSCs. Furthermore, 
ceramide promotes ROS generation, cytocrome c release from mitochondria, 
caspases activation and apoptosis-inducing factor (AIF) nuclear translocation, 
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suggesting that these SL induces apoptosis through both caspase-dependent 
and caspase-independent mechanisms.192  
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AIMS 
 
 
MSCs are the most studied adult stem cells, as they can be isolated from 
almost any tissue, they show a good self-renewal capacity in vitro and they 
also possess good “plasticity”.5 Oddly, MSCs are identified and defined by a 
combination of markers that are not distinctive, as they are shared by other 
cells including fibroblasts. Therefore, pure populations of MSCs cannot be 
isolated, as they are always contaminated by other adult cells that often do not 
possess stem cell plasticity. Thus, it would be very desirable to discover novel 
cell surface markers that would allow to discriminate MSCs from other cells. 
Moreover, new ways to control and promote cell differentiation are needed. 
Thus, it becomes crucial to search for new key molecules that can be 
modulated to increase MSCs differentiation toward the desired tissue or inhibit 
the differentiation when cells have to remain in an undifferentiated state. 
In this direction, we focused our attention on SLs, a family of lipids found in 
the outer leaflet of the plasma membrane and involved in many cell signaling 
pathways.  Therefore, main aims of this work were: 
 
1. to investigate the possible use of SLs as new surface markers for the 
identification, characterization and possibly isolation of human bone 
marrow MSCs; 
2. to investigate the involvement of SLs in the preservation of the 
undifferentiated state of MSCs during in vitro culturing 
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3. to assess the possible role of SLs in the differentiation processes of 
MSCs upon opportune stimuli. 
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CHAPTER 3 - MATERIALS AND METHODS 
 
 
3.1 CELL  CULTURE 
Human BMSCs were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
low glucose (Sigma aldrich) with 10% v/v fetal bovine serum (FBS; HyClone, 
Thermo Scientific), 4 mM L-glutamine, 1% antibiotic-antimycotic (Euroclone) in 
a humidified atmosphere containing 5% CO2 at 37°C. 
 
 
3.2 CELL DIFFERENTIATION TOWARD OSTEOBLASTS 
Confluent BMSCs were diffentiated toward osteoblasts using DMEM low 
glucose 10% FBS with 0,1 uM Dexamethasone, 50 µg/ml L-Ascorbic acid 2-
phosphate and 10 mM β-Glycerophosphate (Sigma Aldrich) for 17 days. At the 
end of differentiation process, Alizarin Red solution (Millipore) was used to 
detect calcium deposition by derived osteoblasts according to the following 
protocol:  
differentiated cells were fixed using iced cold 70% ethanol for 1 hour at room 
temperature (RT). After two washing steps with water, cells were incubated 
with 1 ml of Alizarin Red solution for 30 minutes at RT. At the end of the 
incubation time, Alizarin Red solution was removed and cells were washed 
three times with water to remove the excess color. The stain associated to 
calcium deposition was visualized using a Axiovert 40 microscope (Carl Zeiss 
Microscopy) equipped with a Moticam 2300 camera (Motic) 
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3.3 CELL DIFFERENTIATION TOWARD ADIPOCYTES 
Confluent BMSCs were differentiated toward adipocytes using Mesenchymal 
Stem Cells Adipogenesis Kit (Millipore) according to the manufacturer’s 
instructions. Briefly, cells were differentiated using 1 uM dexamethasone, 500 
uM 3-isobutyl-1-methylxanthine (IBMX), 10 ug/ml insuline and 100 uM 
indomethacine for 21 days. 
At the end of the differentiation process, Oil Red O solution (Millipore) was 
utilized to stain lipid droplets of derived adipocytes according to the following 
protocol: 
differentiated cells were fixed using 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 30 minutes at RT. After two washing steps with water, 
cells were incubated with 1 ml of Oil Red O solution for 50 minutes at RT. At 
the end of the incubation time, Oil Red O solution was removed and cells were 
washed three times with water to remove the excess color. The stain of lipid 
droplets was visualized using a Axiovert 40 microscope equipped with a 
Moticam 2300 camera.  
 
3.4 DIFFERENTIATION TOWARD SMOOTH MUSCLE CELLS 
BMSCs were differentiated toward smooth muscle cells using DMEM low 
glucose 1% FBS with 0,2 ul/ml TGFβ1 (Millipore) for 7 days. 
Immunofluorescence staining was utilized to detect smooth muscle α-actin in 
differentiated cells according to the following protocol: 
cells were fixed using 4% paraformaldeyde (Sigma Aldrich) in PBS for 10 
minutes at RT. After two washing steps with PBS, aspecific binding sites were 
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blocked with a blocking solution (1X PSB, 1% BSA) for 1 hour at RT. Cells 
were incubated with the FITC-conjugated anti-human α-actin (Sigma) at the 
concentration of 1:200 in blocking solution for 1 hour and 15 minutes at RT. 
Cells nucleus were stained with Hoechst 33342 (Sigma Aldrich) at the 
concentration of 1:500 in blocking solution containing 0,1% Triton X100 (Sigma 
Aldrich) for 30 minutes at RT. 
The images were acquired with a Olimpus IX51 fluorescence microscope 
(Olimpus). 
 
3.5 DIFFERENTIATION TOWARD CHONDROCYTES 
For chondrogenic differentiation the pellet culture method was used. BMSCs 
were mantained in 3-D culture in AdvanceSTEM Chondrogenic Differentiation 
Medium (HyClone, Thermo Scientific) for 28 days. At the end of the 
differentiation process, mucopolysaccharides produced by derived 
chondroblasts were detected by Alcian blue staining (Sigma Aldrich) according 
to the following protocol: 
differentiated cells were layered on glass slides and they were fixed using 4% 
paraformaldehyde in PBS for 30 minutes at RT. After two washing steps with 
water, cells were incubated with Alcian blue solution for 1 hour at RT. At the 
end of the incubation time, Alcian Blue solution was removed and cells were 
washed once with 0,1M HCl and twice with water.  The stain of 
mucopolysaccharides was visualized using a Axiovert 40 microscope equipped 
with a Moticam 2300 camera.  
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3.6 FLOW CYTOMETRY ANALYSIS 
 BMSCs were trypsinazed and collected in PBS at a concentration of 2 x 106 
cells/mL. Aspecific binding sites were blocked with a blocking solution (50% 
1X PSB, 50% FBS) for 30 minutes at RT. Cells were stained with antibodies 
against human:  
PE-conjugated CD105, PE-conjugated CD90, FITC-conjugated CD73,  
FITC-conjugated CD11b, PE-conjugated CD45, PerCP-eFluor 710- conjugated 
CD34, FITC-conjugated CD3, FITC-conjugated CD19, FITC-conjugated HLA-
DR (eBioscience) for 10 minutes at 4° C. The respective isotype antibodies 
were used as controls. 
For indirect staining, cells were incubated with primary antibodies against 
human gangliosides GD2 (clone 14.G2a; BD Pharmigen) or GD1a (clone GD1a-
1; Millipore) for 10 minutes at 4° C and then with secondary antibodies PE-
conjugated anti-mouse IgG (eBioscience) or Alexa Fluor 488-conjugated anti-
mouse IgG (Jackson Immuno Research) for 10 minutes at 4° C. 
Samples were acquired with Navios flow cytometer (Beckman Coulter) and 
analysed with Kaluza software (Beckman Coulter) 
 
3.7 METABOLIC LABELING OF CELL SLs 
[3-3H]Sphingosine (Perkin Elmer) dissolved in ethanol was transferred into a 
glass sterile tube and dried under a nitrogen stream; the residue was then 
dissolved in an appropriate volume of DMEM low glucose with 10% FBS to 
obtain a final concentration of 2,4 nM. 
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The medium was added to cells and after 2 hours of incubation (pulse), it was 
replaced with DMEM low glucose with 10% FBS not containing radioactive 
sphingosine for 48 hours (chase). At the end of the chase, cells were washed 
and harvested in ice-cold PBS by scraping. The cell suspension was frozen 
and lyophilized. 
 
3.8 EXTRACTION AND ANALYSIS OF RADIOLABELED SLs 
Total lipids from lyophilized cells were extracted twice with 20:10:1 (v/v) 
chloroform/methanol /water and dried under a nitrogen stream.  
Lipid extract were dissolved in 2:1 (v/v) chloroform/methanol and subjected to 
a two-phase partitioning 20% (v/v) water. 
Radioactive lipids of the aqueous and organic phases obtained after 
partitioning were analysed by high performance thin layer chromatography 
(HPTLC). The solvent system used were 110:40:6 (v/v) 
chloroform/methanol/water and 60:40:9 (v/v) chloroform/methanol/ CaCl2 0,2% 
for the organic and aqueous phases respectively. 
Radioactive lipids were visualized with a Beta-Imager 2000 (Biospace) and 
identified by comparison with radiolabeled standards. The radioactivity 
associated with individual lipids was determined with the specific β–Vision 
software (Biospace) 
 
3.9 ANALYSIS OF ENDOGENOUS SLs 
Total lipids from lyophilized cells were extracted twice with 20:10:1 (v/v) 
chloroform/methanol /water and dried under a nitrogen stream.  
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Lipid extract was dissolved in 2:1 (v/v) chloroform/methanol and subjected to a 
two-phase partitioning 20% (v/v) water to separate the organic phase from the 
aqueous phase. 
Lipids of the organic phase were submitted to an alkaline treatment to remove 
glycerophospholipids. Breafly, the dried organic phase was resuspended in 
100 ul of CHCl3 and 100 ul of 0,6 N NaOH in methanol and allowed to stand at 
37°C for 1 hour. The reaction was blocked by adding 120 ul of 0,5 M HCl in 
methanol. The sample was then submitted to another phase separation and 
the new organic phase was used for HPTLC analysis. 
Markers and gangliosides of the aqueous phase (4 mg of protein/lane) were 
loaded on HPTLC plate , developed in 60:40:9 (v/v) chloroform/methanol/ 0,2% 
CaCl2 and visualised using Earlich’s reagent. Markers and lipids of the organic 
phase (2 mg of protein/lane) were developed in 110:40:6 (v/v) 
chloroform/methanol/water and visualized using Anisaldeide solution.  
 
3.10 CELL SEPARATION BY IMMUNOBEADS 
BMSCs expressing GD2 or GD1a were enriched with immunobeads technique 
(Miltenyi Biotech). Cells were trypsinazed and collected in washing buffer (1X 
PBS, 0,5% BSA, 2 mM EDTA). 2,5 x 106 cells were incubated with 4 ug of 
primary antibody against GD2 or 4 ul of primary antibody against GD1a for 15 
minutes at 4°C. After two washing steps, cells were incubated with 30 ul of 
anti-mouse IgG microbeads (Miltenyi Biotech) for 15 minutes at 4°C. Cells were 
then washed twice and resuspended in 500 ul of washing buffer. The columns 
used for cell separation were placed in a octoMACS Separator (Miltenyi 
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Biotech) and prepared by rinsing 500 ul of washing buffer. The cell 
suspensions were added to the columns. The unlabeled cells passed through 
the columns and were collected while magnetically labeled cells remained 
attached to the columns. These cells were then eluted with 1 ml of washing 
buffer in separate collection tubes by removing the columns from the separator 
and by firmly pushing the plunger into the columns. 
 
3.11 RNA EXTRACTION AND QUANTITATIVE PCR 
Total RNA was isolated using RNeasy Mini Kit (Qiagen) and 0,8 ug of extracted 
RNA was reversed transcribed to cDNA using iScript cDNA Synthesis Kit 
(Biorad) according to the manufacturers’s instruction. Realtime PCR was 
performed with 10 ng of cDNA as template, 0,2 uM primers and 1X iQ Custom 
SYBR Green Supermix (Biorad) in a 20 ul final volume using 7900 HT Fast Real 
time PCR System instrument (Applied Biosystems). 
The following primers were used to amplify target genes: human alkaline 
phosphatase (ALP) forward 5’-CGCACGGAACTCCTGACC-3’ and reverse 5’-
GCCACCACCACCATCTCG-3’, human osteopontin (SPP1) F5’- 
TGCTACAGACGAGGACATCA-3’ and  
R5’-GTCATCCAGCTGACTCGTTT-3’, human runt-related transcription factor 2 
(RUNX2)  
F5’-CACCATGTCAGCAAAACTTCTT-3’ and R5’-TCACGTCGCTCATTTTGC-3’, 
R5’-CGGACTGTGTCTGCTGTGTT-3’. Human tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein zeta 
polypeptide (YWHAZ) F5’-GATCCCCAATGCTTCACAAG-3’ and  
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R5’-TGCTTGTTGTGACTGATCGAC-3’ primers were used to amplify reference 
gene. The following amplification program was used: initial denaturation at 
95°C for 3 min, followed by 40 cycles of 5 sec each at 95°C and 30 sec at 
56°C. Relative quantification of target genes was performed in triplicate and 
was calculated by the equation 2-ΔΔCt 
 
3.12 HPTLC-MASS SPECTROMETRY 
After development, HPTLC plates were placed into the ImagePrep device 
(Bruker Daltonics) and matrix layer was added by repeating three identical 
phases with 8 spray cycles, followed by 30 seconds incubation time and 30 
seconds of drying time (four phases for neutral GSLs). Subsequently, HPTLC 
plates were placed on the MTP TLC adapter (Bruker Daltonics) and transferred 
to MALDI mass spectrometer. 
Spectra were acquired in reflector negative modality depending by using an 
Ultraflex III ToF/ToF mass spectrometer equipped with Smartbeam laser 
(frequency of 100 Hz, Bruker Daltonics) and FlexControl software v. 3.3 (Bruker 
Daltonics). Spectrometer settings were ion source 1, 20 kV; ion source 2, 17.2 
kV; lens, 7.4 kV; reflector 21 kV; reflector 2, 11 kV; mass suppression up to m/z 
800; pulsed ion extraction, 200 ns; detector gain voltage, 1552 V; electronic 
gain, 100 mV/full scale. 
SurveyViewer software v.1.1 (Bruker Daltonics) was employed.. Spectra of 
interest were then analyzed by FlexAnalysis software v. 3.3 (Bruker Daltonics). 
The attribution of spectra to gangliosides was made by the  LIPID MAPS 
structure database (LMSD, Sud M., Fahy E., Cotter D., Brown A., Dennis E., 
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Glass C., Murphy R., Raetz C., Russell D., and Subramaniam S., Nucleic Acids 
Research 35, D527-32 (2006)) with a GSLs MS precursor ion analysis tool 
(LIPID MAPS online tools for lipid research. Fahy E, Sud M, Cotter D and 
Subramaniam S. Nucleic Acids Research 35, W606-12 (2007)). 
 
3.13 ALKALINE PHOSPHATASE ACTIVITY QUANTIFICATION 
Alkaline Phosphatase was quantified in GD1a positive and GD1a negative 
BMSCs differentiated to osteoblasts and in non-differentiated BMSCs as 
control using Quantitative Alkaline Phosphatase ES Characterization kit 
(Millipore) according to the manufacturer’s instructions. Cells were washed and 
harvested in PBS by scraping, collected in 1X Wash Solution for counting and 
centrifugated at 1200 rpm for 6 minutes. 45000 cells for each sample were 
resuspended in 150 ul of p-NPP Buffer and tranferred to 3 wells of a 96-well 
plate (15000 cells/well). The enzymatic reaction was performed adding 50 ul of 
2X p-NPP Substrate Solution to each sample and incubating for 20 minutes at 
RT in the dark. At the end of the incubation time, reaction was stopped by 
adding 50 ul of Reaction Stop Solution. The amount of p-nitrophenol, a yellow 
colored by-product of the catalytic reaction, was mesured reading the 
absorbance at 405 nm using Victor3 plate reader (Perkin Elmer). 
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CHAPTER 4 - RESULTS 
 
 
 
4.1 BMSCs CHARACTERIZATION 
Human MSCs extracted from bone marrow of different donors showed the 
characteristic features of spindle shape and plastic adherence. The culture-
expanded cells were capable of in vitro differentiation to osteoblasts as 
demonstrated by alizarin red staining (fig. 1 A), to adipocyte as demonstrated 
by oil red staining (fig 1 B), to smooth muscle cells as demonstrated by smooth 
muscle α-actin immunofluorescence staining (fig. 1 C) and to chondroblasts as 
demonstrated by alcian blu staining. (fig. 1D) Cytofluorimetric analysis was 
performed to test the expression of currently used MSCs markers and the 
absence of hematopoietic and endothelial antigens. BMSCs resulted to be 
CD73+, CD90+, CD105+, CD3-, CD11b-, CD19-, CD34-, CD45- and HLA-DR- as 
expected. (fig. 1E) 
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Figure 1  (A) Alizarin red stain, (B) oil red o stain, (C) 
immunofluorescence staining of smooth muscle α-actin 
using FITC-conjugated anti-human α-actin antibody and  
(D) alcian Blue stain. (E) Flow cytometry analysis of antigens 
commonly used to define BMSCs: CD73, CD90, CD105, 
CD3, CD11b, CD19, CD34, CD45 and HLA-DR ( the peaks 
of specific antigens are shown in yellow while the peaks of 
respective isotype controls are shown in red). 
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4.2 ANALYSIS OF SL PATTERN  
SL pattern of BMSCs was analyzed by metabolic labeling of cell sphingolipids 
with [1-3H]Sphingosine, as described in the Methods. Cells were collected and,  
after lipids extraction, the organic and aqueous phase radiolabeled 
sphingolipids were separated by HPTLC and quantified by 
radiochromatoscanning (fig. 2 A and C). In the organic phase, we found that 
BMSCs expressed mainly SM, Gb4, and Gb3As, as shown in the percentage 
distribution graph (fig. 2B). On the other hand, SLs found in the aqueous phase 
were mainly a-series gangliosides, GM3 being the most abundant, and the b-
series ganglioside GD3 (fig. 2 D). Surprisingly, ganglioside GD2, that was 
proposed by Martinez et al. as a marker for BMSCs characterization and 
isolation, could not be detected in any of the sample analyzed. Results 
obtained from radiolabeled SLs analyses confirmed the results obtained by the 
less sensitive methodology of HPTLC separation of BMSCs endogenous non-
radiolabeled SLs (fig. 2A and C, first lanes). 
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Figure 2 SL pattern of BMSCs. Cells were metabolically labelled with  
[3-3H]sphingosine and after lipid extraction organic and aqueous phase SLs were 
separated by HPTLC. 
Top panel: (A) HPTLC separation of BMSCs organic phase SLs developed in 
110:40:6 (v/v) chloroform/methanol/water solvent. Radiochromatoscanning 
images of endogenous GSLs visualized using Anisaldeide solution and 
radiolebeled GSLs visualized with a Beta-Imager 2000. (B) Percentage 
distribution of radiolebeled GSLs.  
Bottom panel: HPTLC separation of BMSCs aqueous phase gangliosides 
developed in 60:40:9 (v/v) chloroform/methanol/0,2% CaCl2. solvent. 
Radiochromatoscanning images of endogenous gangliosides visualised using 
Earlich’s reagent and radioalebeld gangliosides visualised with a Beta-Imager 
2000. (D) Percentage distribution of radioalebeled gangliosides The radioactivity 
associated with individual lipids was determined with the specific !–Vision 
software. Data are means ±SD of five different experiments..  
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4.3 ANALYSIS OF GD2 EXPRESSION BY HPTLC-MASS SPECTROMETRY 
To further investigate the presence of ganglioside GD2 in BMSCs, cell 
sphingolipids were analyzed also by a combined HPTLC-mass spectrometry 
approach. Mass spectra were acquired in negative reflection mode by direct 
coupling of the HPTLC of endogenous non-radiolabeled SLs with a MALDI 
mass spectrometer. Figure 3 shows representative radiochromatoscanning 
images of HPTLC separation of (A) BMSCs radiolabeled gangliosides, (C) 
BMSCs radiolabeled gangliosides spiked with GD2 standard and (E) GD2 
standard alone as positive control. No signal corresponding to GD2 was 
detected in any of the representative mass spectra obtained from the analysis 
of BMSCs gangliosides (fig. 3 B). On the contrary, signals corresponding to 
GD2 were observed in mass spectra obtained from the analysis of gangliosides 
spiked with GD2 standard. In particular, peaks at 1673,92 m/z and at 1701,92 
m/z correspond to GD2 d18:1, C18:0 [M-H]- and C20:0 [M-H]-, respectively, 
and peaks at 1694,92 m/z and 1722,92 correspond to C18:0 [M+Na-2H]- and 
to C20:0 [M+Na-2H]- (Fig. 3D). Mass spectra obtained from the analysis of GD2 
standard alone showed signals corresponding to GD2 as expected. In 
particular, peaks at 1673,92 m/z and at 1701,92 m/z correspond to GD2 d18:1, 
C18:0 [M-H]- and C20:0 [M-H]-, respectively, and peaks at 1694,92 m/z and 
1722,92 correspond to C18:0 [M+Na-2H]- and to C20:0 [M+Na-2H]- (Fig. 3F). 
These data confirmed results obtained with HPTLC analysis demonstrating 
that ganglioside GD2 was not expressed in BMSCs. 
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 Figure 3 HPTLC separation and mass spectrometry.   
(A) Representative radiochromatoscanning image of BMSCs radiolabeled 
gangliosides. The close up of the image shows the area corresponding to 
GD2 standard band position analyzed by mass spectrometer. (B) No 
signals were detected in spectra of the acquired region, from 14,5 to 19 
mm with a 0,5 mm gap. (C) Representative radiochromatoscanning image 
of BMSCs radiolabeled gangliosides spiked with GD2 standard. The close 
up of the area of GD2 standard shows mass spectra of the ganglioside. (D) 
Peaks at 1673,92 m/z and at 1701,92 m/z correspond to GD2 d18:1, C18:0 
[M-H]- and C20:0 [M-H]-, respectively, and peaks at1694,92 m/z and 
1722,92 correspond to C18:0 [M+Na-2H]- and to C20:0 [M+Na-2H]-. (E) 
Representative radiochromatoscanning image of GD2 standard alone. The 
close up of the area of the region corresponding to GD2 standard shows 
the mass spectra of the ganglioside. (F) Peaks at 1673,92 m/z and at 
1701,92 m/z correspond to GD2 d18:1, C18:0 [M-H]- and C20:0 [M-H]-, 
respectively, and peaks at1694,92 m/z and 1722,92 correspond to C18:0 
[M+Na-2H]- and to C20:0 [M+Na-2H]-. 
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4.4 ANALYSIS OF GD2 EXPRESSION BY IMMUNOLOGICAL TECHNIQUES 
Successively, we investigated whether discrepancies between our results 
(showing an undetectable level of ganglioside GD2 in BMSCs)  and the 
published data (suggesting GD2 as a new BMSCs marker) were caused by the 
different analytical methodology used. In particular, as antibodies are often 
unspecific in recognizing small non-proteic epitopes, we tested whether we 
could observe GD2-positivity by immunohistochemistry in the same samples, 
which we previously found negative for GD2 expression. Therefore, we 
analyzed BMSCs by cytofluorimetry, using the same anti-GD2 antibody used 
by Martinez et al. Surprisingly, under these conditions, we observed that 
19,5% ± 5% of all BMSC samples analyzed were positive for GD2. (fig. 4 A) 
Thus, to test whether the observed results could be due to an unspecific 
binding of the GD2-antibody, we tried to enrich the GD2-positive population by 
sorting cells with immunobeads carrying the anti-GD2 antibody. The so called 
“positive” and “negative” fractions were collected and analyzed by 
cytofluorimetry, to test whether the enrichment step was successful. 
Interestingly, the positive fraction was 70,5% ± 10,8% positive by FACS 
analysis, while the negative fraction was only 9,7% ± 4,5%, confirming that the 
antibody was specifically binding to a fraction of BMSCs (Fig. 4 C and D). 
Nonetheless, these results do not clarify if the recognized epitope is really GD2 
or the antibody is binding some other molecule. Therefore, we analyzed the 
sphingolipid pattern of both positive and negative cell fractions by metabolic 
labeling of cell sphingolipids with [1-3H]Sphingosine followed by HPTLC 
separation and analysis with radiochromatoscanning. We found almost 
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superimposable sphingolipid patterns in the two cell populations. In particular, 
GD2 could not be detected in the negative but also in the positive cell fraction, 
suggesting that anti-GD2 antibody possibly recognized other targets (Fig. 4 E 
and F). These results may support the notion that GD2 antibody can also 
cross-react with other sialo-glycoconjugates,  which have yet to be identified.  
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Figure 4 Immunoselection of BMSCs for ganglioside GD2. 
(A) Flow cytometry analysis of GD2 expression in BMSCs.  
(B) Schematic image of immunobeads separation protocol (Miltenyi 
Biotech). (C-D) Flow cytometry analysis of GD2 expression in GD2 
positive (C) and GD2 negative (D) cell fractions obtained after 
immuobeads separation. (E) Radiochromatoscanning image of 
HPTLC separation of radiolabelled gangliosides: lane 1: unsorted 
BMSCs gangliosides, lane 2: GD2 positive BMSCs gangliosides, 
lane 3: GD2 negative BMSCs gangliosides.  
 (F) Percentage distribution of radiolabelled gangliosides. Data are 
means ±SD of three different experiments. 
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4.5 ANALYSIS OF SL PATTERN MODULATION DURING BMSCs 
DIFFERENTIATION 
The SL pattern of BMSCs was then studied during stem cell differentiation, to 
assess a possible involvement of SLs in the process. Thus, the initial 
sphingolipid pattern of BMSCs isolated from five different donors was analyzed 
by metabolic labeling of cell sphingolipids with [1-3H]sphingosine, as previously 
described (fig. 6 A). We found small variability in gangliosides distribution 
among BMSCs from different donors (fig. 6 B). Then, cell were induced to 
differentiate and acquire the osteoblastic phenotype, by culturing cells in the 
appropriate differentiation medium, as described in the Methods section. The 
differentiation process is usually completed within 2-3 weeks from induction. 
Nonetheless, in order to investigate the possible involvement of some 
particular SLs in the induction of the differentiation process, we focused our 
attention on the early phases of the process. Therefore, we analyzed the SL 
pattern modifications at day 5 from differentiation, where some crucial 
osteogenic genes are known to be already activated. In fact, ALP gene 
expression was about 9,8-fold higher in BMSCs induced to osteogenic 
differentiation respect to undifferentiated cells (fig. 5). 
Metabolic radiolabelling with [3-3H]sphingosine revealed a significant decrease 
(23% reduction) of GM3 content at day 5 of differentiation, whereas a-series 
gangliosides markedly increased, in particular GM2, GM1 and GD1a (54,2%, 
50,7% and 72,3% increase, respectively, Figure 6 D). On the contrary, we did 
not observe a significant change in ganglioside GD3 content (Fig 6 D) as well 
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as in organic phase SLs between differentiated BMSCs and control 
undifferentiated cells (fig. 6 E and F)  
 
 
 
 
 
 
 
 
 
 
 
Figure 5 
Figure 5 Realtime PCR analysis of ALP in BMSCs 
induced to differentiate toward osteoblasts for 5 days. 
Undifferentiated BMSCs were used as control. Data 
shown are means ± SD ot three different experiments. 
Statistical differences were determined by 1- way Anova:  
*** P<0.0001 compared to respective controls. 
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Figure 6 
Figure 6 (A) Radiochromatoscanning image of HPTLC separation of radiolabeled 
gangliosides extracted from BMSCs of different donors. (B) Percentage distribution of 
radiolabeled gangliosides. Data are means ±SD of three different experiments. (C) 
Radiochromatoscanning image of HPTLC separation of aqueous phase radiolebeled 
gangliosides extracted from BMSCs differentiated toward osteoblasts. Lane 1: gangliosides 
of control undifferentiated BMSCs, lane 2: gangliosides of BMSCs differentiating toward 
osteoblasts. (D) Percentage distribution of radiolabeled gangliosides. (E) 
Radiochromatoscanning image of HPTLC separation of radiolebeled organic phase SLs 
extracted from BMSCs differentiated toward osteoblasts. Lane 1: SLs of control 
undifferentiated BMSCs, lane 2: SLs of BMSCs differentiating toward osteoblasts Data are 
means ±SD of three different experiments, statistical differences were determined by 1- way 
Anova: **P<0.001 and *** P<0.0001 compared to control. 
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4.6 BMSCs ENRICHMENT IN GANGLIOSIDE GD1a 
As ganglioside GD1a expression greatly increased during osteogenesis, we 
tested if this ganglioside could represent a new early marker of stem cell 
commitment toward bone differentiation. Therefore, we checked if we could 
enrich the initial BMSCs population in GD1a using the opportune antibody. 
Based on the previous unsuccessful results with GD2, we first needed to 
assess if the anti-GD1a antibody could specifically bind GD1. Therefore, we 
first analyzed cells by cytofluorimetry and found that only 25% ± 6% of the cell 
population was positive for GD1a. Therefore, we envisioned the possibility of 
selecting, or at least enriching, this GD1a positive sub-population using 
immunobeads sorting, as previously described for GD2. After immunobeads 
sorting, results confirmed that we could indeed obtain two populations, one 
highly enriched in GD1a (94% ± 9% positive), and one putatively GD1a 
negative (13 ± 4,5)  (fig. 7 A). Differently from our previous attempts with GD2, 
metabolic radiolabelling with [3-3H]sphingosine (fig. 7 B) revealed that the two 
cell fractions (GD1a positive and negative) possessed different expression of 
GD1a. In fact, in the positive fraction GD1a percentual content was 5,4 
whereas in the negative one only 0,98. (Fig. 7 C) 
 
 
4.7 ANALYSIS OF OSTEOGENIC POTENTIAL OF GD1a POSITIVE AND 
GD1a NEGATIVE BMSCs 
To test the hypothesis that GD1a could represent a marker of BMSCs initial 
commitment to the osteogenic phenotype, we analyzed gene expression of 
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osteogenic markers genes ALP, osteopontin and RUNX2 in GD1a positive and 
GD1a negative cells, and compared the results to unsorted BMSCs. Analysis 
of gene expression by qPCR revealed that GD1a positive BMSCs possessed 
significantly higher mRNA levels of all osteogenic markers analyzed as 
compared to the GD1a negative fraction, as shown in Fig. 7 D, E, F. In 
particular in GD1a positive BMSCs ALP, osteopontin and RUNX2 gene 
expressions were 2,3-fold, 2,6-fold and 0,5-fold increased, respectively, in 
comparison to GD1a negative BMSCs. 
Then, we tested whether the initial osteogenic commitment of GD1a-positive 
BMSCs could affect the differentiation process. Therefore, GD1a-positive and 
–negative cell fractions were induced to differentiate toward osteoblasts, as 
previously described. At the end of the differentiation process, which was 
carried out for 3 weeks, we checked the expression of osteogenic markers 
ALP, osteopontin and RUNX2. Undifferentiated, unsorted BMSCs were used 
as controls. Results confirmed a significantly higher expression of all 
osteogenic markers in differentiated osteoblasts originated from GD1a-positive 
cells (Fig. 6 G,H,I). In particular, we registered a 1,2-fold increase of ALP, 2,4- 
fold increase of osteopontin and 1,2-fold increase of RUNX2 in differentiated 
GD1a positive cells respect to differentiated negative ones. To further confirm 
that GD1a-positivity enhanced the induced osteogenesis, the enzymatic 
activity of ALP was also measured at the end of the differentiation process. We 
found that ALP enzymatic activity was almost 3-fold higher in osteoblasts 
originated from GD1a-positive BMSCs as compared to those obtained from 
GD1a negative ones (Fig. 6 J). 
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Figure 7 Immunobeads separation of BMSCs for ganglioside GD1a. 
(A) Flow cytometry analysis of GD1a expression in BMSCs and in GD1a negative 
and GD1a positive cell fractions obtained after immunoselection. (B) 
Radiochromatoscanning image of HPTLC separation of radioalebeld ganglioside: 
lane 1: unsorted BMSCs gangliosides, lane 2: GD1a positive BMSCs 
gangliosides, lane 3: GD1a negative BMSCs gangliosides. (C) Percentage 
distribution of radiolebeled gangliosides. (D-F) Realtime PCR analysis of ALP, 
osteopontin and RUNX2 gene expression in GD1a positive and negative BMSCs 
compared to unsorted undifferentiated BMSCs. (G-I) Realtime PCR analysis of 
ALP, osteopontin and RUNX2 gene expression in GD1a positive and negative 
BMSCs differentiated toward osteoblasts compared to unsorted undifferentiated 
BMSCs. (J) Graph showing ALP activity in GD1a positive and negative BMSCs 
differentiated toward osteoblasts and in unsorted undifferentiated BMSCs as 
control. Data shown are means ±SD of three different experiments, statistical 
differences were determined by 1- way Anova: *P<0.05 , **P<0.001 and *** 
P<0.0001 compared to respective controls. 
 
 
 
 
 
 
Figure 7 
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CHAPTER 5 - DISCUSSION 
 
 
Despite the recent advances in the stem cell field, many issues of stem cells 
biology and their clinical use remain unresolved. MSCs derived from different 
tissues were extensively investigated in the last few years. However, there is 
still a lack of specific cell markers for the identification of these cells. 
 In fact, MSCs are currently defined by a combination of physical, phenotypic 
and functional properties and novel cell- surface markers are therefore needed 
for their quick characterization and isolation from tissues. In this work, SLs, a 
class of lipids principally localized in plasma membrane and involved in many 
cell signaling pathways, were investigated as possible cell surface markers for 
BMSCs identification.  
We first characterized MSCs isolated from bone marrow of different donors 
through cytofluorimetric analysis. As expected, these cells expressed the 
typical MSCs markers CD90, CD105 and CD73 and lack the expression of 
hematopoietic and endothelial antigens. Moreover, cells were able to 
differentiate toward osteoblasts, adipocytes, chondroblasts and smooth 
muscle cells demonstrating the tipical multi-lineage differentiation ability of 
MSCs. 
The analysis of SL pattern was performed according to metabolic labeling of 
cells SLs with [3-3H]sphingosine, an established methodology which has been 
used and perfected in our laboratory in the past several years. Radiolabeled 
SLs were extracted and partitioned into an organic and an aqueous phases, 
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and then subjected to chromatography on HPTLC plates. Regarding the 
organic phase SLs, BMSCs expressed principally SM, an important element of 
all plasma membranes, and the globo-serie SLs Gb4 and Gb3. Among 
aqueous phase SLs, we found that BMSCs expressed mainly gangliosides of 
a-series, such as GM3, GM2 and GD1a, and b-series ganglioside GD3. Our 
findings are in contrast with those published by Martinez and colleagues,180 
who reported the expression of the b-series ganglioside GD2 in BMSCs, which 
they proposed as a novel surface marker for BMSCs identification and 
isolation.  
Therefore, to better investigate GD2 content of BMSCs, we developed a new 
combined HPTLC-MALDI mass spectrometry approach, in collaboration with 
some colleagues from our Department. This method allowed us to directly 
obtain the mass spectra of cells endogenous gangliosides separated by 
HPTLC. Results confirmed the sphingolipid pattern that we could observe 
using metabolic labeling, and GD2 ganglioside could not be detected in any of 
the analyzed samples.  
At this point, we decided to investigate whether discrepancies between our 
and published data on GD2 expression in BMSCs were caused by the different 
analytical methodology used. Indeed, Martinez and colleagues demonstrated 
GD2 expression in BMSCs only through immunological techniques, using an 
anti-GD2 antibody.  Unfortunately, although widely used, antibodies against 
gangliosides are not always specific, as they may recognize saccharide 
moieties present on other glyococonjugates or glycoproteins. Along this line, 
Apostolski and colleagues reported that a subset of human anti-GM1 
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antibodies cross-react with Gal(beta 1-3)GalNAc bearing glycoproteins in 
peripheral nerve and spinal cord.193 Moreover, Thomas and colleagues 
demonstrated that IgM monoclonal antibodies binding ganglioside GD1b, 
recognize also several glycoproteins in the central and peripheral nervous 
system194. Therefore, as antibodies are often unspecific in recognizing non-
proteic molecules, we tested if we could observe GD2-positivity in BMSCs 
through cytofluorimetric analysis, using the same anti-GD2 antibody used in 
the published work mentioned above. Actually, we found that a subpopulation 
of BMSCs was linked by this antibody. Moreover, we could separate this 
subpopulation using immunobeads linked with anti-GD2 antibody. The cell 
fraction obtained after separation resulted GD2 positive according to 
cytofluorimetric analysis. Therefore, we checked by biochemical analysis 
whether this cell population really expressed ganglioside GD2. Results of 
HPTLC separation showed that GD2 positive BMSCs had the same 
ganglioside pattern as GD2 negative ones. In particular, GD2 was not 
detectable in any of the analyzed fractions, suggesting that in these cells, the 
anti-GD2 antibody possibly recognized other targets than GD2.  
These results underlined that antibodies should always be used with great 
caution, and that multiple analytical approaches should be always used, 
especially when analyzing small non-proteic biomolecules. Therefore, we tend 
to exclude that ganglioside GD2 could be elected as specific BMSCs marker, 
although it would be useful to analyze cells isolated by other labs. 
Nonetheless, as SLs are key molecules involved in cell proliferation and 
differentiation, we tested if other sphingolipids, besides GD2, could be used as 
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stem cell markers and/or could be involved in BMSC differentiation. Therefore, 
in the second part of this thesis work, we focused our attention on SLs role in 
cell differentiation process. MSCs are known to possess the potential to 
differentiate into many different tissues. However, one of the main problems 
linked to the use of these cells in regenerative medicine is that the number of 
cells that differentiate into the desired phenotype, upon opportune stimulation, 
is often too low. Moreover, the mechanism by which they repair damaged 
tissues in vivo is still poorly understood and we are not able to drive 
differentiation and cell behavior in a controlled fashion. Published data 
revealed that SL pattern of adult stem cells significantly changes with cell 
differentiation. In particular, it was demonstrated that in human ADMSCs  
GD1a content increases  after 5 days of differentiation toward osteoblasts. (lee) 
Moreover, in MSCs from dental pulp, it was observed an increase of 
ganglioside GD1a together with a decrease of ganglioside GM3 during 
differentiation toward osteoblasts.185 
Based on these premises, we wanted to investigate whether SLs content of 
BMSCs was modulated during differentiation toward osteoblasts and whether 
its modulation was directly linked to the differentiation process. We initially 
observed that ganglioside pattern of BMSCs strongly changed during the 
differentiation. In particular, we registered a strong increase of a-series 
gangliosides GM2 and GD1a already after 5 days of osteogenic induction. To 
test if GD1a could be implicated in osteoblasts differentiation, we first analyzed 
the expression of osteogenic markers genes ALP, osteopontin and RUNX2, in 
GD1a positive and GD1a negative BMSCs. ALP gene is not specifically 
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expressed by osteoblasts. However, its expression notably increases after 
osteogenic induction and it is considered, together with osteopontin, an early 
marker of osteogenic differentiation. Results of quantitative PCR showed that 
the expression of ALP and osteopontin was significantly higher in GD1a 
positive cells than in GD1a negative ones. Moreover, the expression of RUNX2, 
a transcription factor essential for the differentiation toward osteoblasts, 
resulted to be increased in GD1a positive cells compared to GD1a negative 
ones. Consequently, we decided to evaluate the osteogenic potential of GD1a 
positive as compared to that of GD1a-negative BMSCs. Results indicated that 
the subpopulation of BMSCs expressing GD1a had a higher osteogenic 
potential as compared to GD1a negative BMSCs. This was possibly caused by 
an initial osteogenic commitment of GD1a-positive BMSCs, as they possessed 
higher basal level of osteogenic markers, as compared to the GD1a-negative 
cell fraction. Therefore, these data suggest that GD1a positive BMSCs may 
represent a sub-population of mesenchymal progenitor cells which are already 
partially committed to osteogenic differentiation. On the contrary, GD1a 
negative BMSCs could represent a more undifferentiated subpopulation of 
MSCs. Therefore, we are currently investigating whether GD1a-negative 
BMSCs, beeing a more undifferentiated cell population, posses a higher 
plasticity due to less commitment. Moreover, the role of the other SLs that we 
found modulated upon BMSCs differentiation (GM3, GM2 and GM1) is also 
under further investigation. 
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